VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the…

Source

Previous articleDoing Things Differently: Beyond Business as Usual in the Psychedelics Space
Next articleLate-Stage Psychedelic Trials: A brief review of the two most mature psychedelic drug development programs